Ophthalmology Advisory Boards

+ Expand all

Glaucoma Advisory Board

Paul Austin Chandler Professor of Ophthalmology, Vice Chair for Clinical Research in Ophthalmology, Co-Director, Glaucoma Center of Excellence, Harvard Medical School Associate Director, Ocular Genomics Institute Associate Director, Howe Laboratory Associate Chief for Ophthalmology Clinical Research Senior Scientist Associate Member, Broad Institute of Harvard and MIT Massachusetts Eye and Ear, Boston, MA

Janey L. Wiggs, M.D., Ph.D. is a physician scientist at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. She is currently the Paul Austin Chandler Professor of Ophthalmology and is the Vice Chair for Clinical Research in Ophthalmology at Harvard Medical School. She also directs the CLIA-certified genetic testing laboratory at the Massachusetts Eye and Ear Infirmary and is a co-director of the Ocular Genomics Institute and co-director of the Glaucoma Center of Excellence.

Dr. Wiggs received her B.A. and Ph.D. degrees in biochemistry from the University of California at Berkeley and her M.D. degree from Harvard Medical School. She did post-doctoral training in molecular genetics under the direction of Dr. Ted Dryja. Dr. Wiggs completed the ophthalmology residency at the Massachusetts Eye and Ear Infirmary and received fellowship training in glaucoma and also in medical genetics and is certified by the both the American Board of Ophthalmology and the American Board of Medical Genetics. Dr. Wiggs’ research program is focused on the discovery and characterization of genetic factors that contribute to the blinding eye disease glaucoma and is funded by the National Eye Institute (NEI) as well as other nonprofit foundations. She is investigating the genetic etiologies of both early-onset and adult forms of glaucoma and is the PI of the NEIGHBORHOOD consortium for gene discovery in primary open angle glaucoma and is a founding member of the International Glaucoma Genetics Consortium (IGGC). She has also participated in research programs funded by the US-INDO joint working group (NEI) and the NEI eyeGENE consortium.

Dr. Wiggs was the inaugural chair of the Genetics Group for ARVO and is an ARVO gold fellow. She currently serves on the editorial boards of IOVS, JAMA Ophthalmology, Molecular Vision, Journal of Glaucoma, and Annual Reviews in Vision Science. She is a member of the scientific advisory boards for the Glaucoma Research Foundation, Research to Prevent Blindness and the Glaucoma Foundation, and is a past member of the Advisory Council of the National Eye Institute. She has received the Heed Award, the Heed/Knapp Award, the Research to Prevent Blindness Scholar Award, the AAO Honor Award, the Lew Wasserman Merit Award, the Alcon Research Award, the David L. Epstein award from the ARVO Foundation and was a winner of the NEI Audacious Goal competition. She has delivered the American Glaucoma Society Clinician-Scientist lecture and the American Academy of Ophthalmology Shaffer Lecture. She is an elected member of the Glaucoma Research Society, the American Ophthalmological Society, the Academia Ophthalmologica Internationalis and the National Academy of Medicine.

W. Daniel Stamer, Ph.D. currently serves as the Joseph A.C. Wadsworth Professor of Ophthalmology and Professor of Biomedical Engineering at Duke University. Professor Stamer was educated at the University of Arizona, earning his bachelors of science in Molecular and Cellular Biology in 1990 and doctorate in Pharmacology and Toxicology in 1996. He completed two research fellowships: the first with Dr. Andrea Yool in electrophysiology and the second with Dr. David Epstein in glaucoma/cell biology. Professor Stamer started his research program in 1998 at the University of Arizona, where he remained for 14 years, rising through the ranks to full Professor and Director of Ophthalmic Research. He joined the faculty at the Duke Eye Center 6 years ago. Notable recent accomplishments include the Rudin Prize for Glaucoma in 2012, the Research to Prevent Blindness Senior Scientific Investigator Award in 2013 and election as ARVO trustee in 2015. He currently holds prominent editorial positions in three premier ophthalmology journals: as Editor-in-Chief for the Journal of Ocular Pharmacology and Therapeutics, member of editorial board Investigative Ophthalmology and Visual Science and executive editor of Experimental Eye Research.

The primary research focus of the Stamer laboratory is to understand the molecular and cellular mechanisms that regulate conventional outflow such that novel targets can be identified, validated and used for the development of therapeutics that target/modify the diseased tissue responsible for elevated intraocular pressure in glaucoma. Professor Stamer has been working in the area of glaucoma research for the past 25 years, pioneering cellular, tissue, organ culture and murine model systems for use by his laboratory and others to study conventional outflow physiology and pharmacology. His laboratory has worked closely with industry, assisting in the development/pre-clinical testing of several new classes of glaucoma drugs that target the diseased conventional outflow pathway responsible for ocular hypertension.

Research progress by the Stamer laboratory group is documented in over 130 peer-reviewed manuscripts and two dozen reviews/book chapters/editorials.

Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service. After receiving an undergraduate degree majoring in Biology and Economics at McGill University, he received his MD and MPH degrees from the Johns Hopkins University and was a Dana Foundation Fellow at the Wilmer Eye Institute, Johns Hopkins Hospital. Following residency training at the Casey Eye Institute and a Heed Foundation Fellowship at the Bascom Palmer Eye Institute, Dr. Singh joined the Stanford faculty in 1992. He has published over 300 papers, book chapters, monographs and abstracts including over 200 original peer-reviewed articles, delivered over 350 invited lectures on six continents, edited three textbooks and served on the editorial boards of ten ophthalmic publications. Dr. Singh’s current research interests include glaucoma and cataract surgical trials, the epidemiology of myopia and glaucoma, ophthalmic genetics as well as health care delivery in underserved communities in the United States and overseas. He is an investigator in the National Institutes of Health funded NEI Glaucoma Human Genetics Collaboration and is funded by the U.S. Food and Drug Administration (FDA) to study patient related outcomes with minimally invasive glaucoma surgery. Dr. Singh's clinical practice focuses on the medical, laser and surgical management of glaucoma and cataract.

Dr. Singh has served as President of the American Glaucoma Society, Executive Vice President of the World Glaucoma Association and Board Chair for the Glaucoma Research Foundation and serves on the Senior Advisory Committee of the International Society of Glaucoma Surgery.

He serves as a member of the FDA Advisory Committee on Ophthalmic Devices and as an advisor to the UCSF/Stanford Center for Excellence in Regulatory Science and Innovation (CERSI) which is an FDA funded initiative. As a CERSI advisor, Dr. Singh developed the concept of an Innovations in Regulatory Science Summit for which he serves on the organizing committee. Dr. Singh has served as a consultant for the National Space Biomedical Research Institute for which he assists NASA in solving eye problems related to space travel and was co-chair of the Association for Research in Vision and Ophthalmology ARVO/ARVO Asia Translational Vision Summit Steering Committee. He received the 2015 Life Achievement Honor Award from the American Academy of Ophthalmology (AAO) and delivered the Keynote American Glaucoma Society Lecture at the 2017 AAO Glaucoma Subspecialty Meeting.

Dr. Singh served as an Academic Advising Dean at the School of Medicine from 2002-2005 and two three year terms as an elected at-large member of the Faculty Senate from 2006-2012. He received the 2006 School of Medicine Franklin G. Ebaugh Jr. Award and was one of two recipients of the 2012 University-wide Asian American Faculty Award. Dr. Singh currently serves on the Organizing Committee of the annual Stanford Drug Discovery Symposium and is co-chair of Ophthalmology Futures Forum, a global ophthalmic innovation meeting.

In 2013, Dr. Singh was the second American to receive the World Glaucoma Association Founder's Award, the biennially presented highest honor of the Association. In 2014, he was inducted into the Delta Omega Public Health Honor Society at the Johns Hopkins University Bloomberg School of Public Health as a distinguished alumnus. A global nomination-based survey conducted in 2018 by The Ophthalmologist, a U.K. based publication, ranked Dr. Singh as one of the 15 most influential individuals in ophthalmology worldwide.

President, PharmaLogic Development, Inc., Clinical Professor, Ophthalmology & Visual Sciences, University of California, Davis Gary D. Novack, Ph.D. is the founder and president of PharmaLogic Development, Inc. Dr. Novack studied at University of California campuses (BA, UC Santa Cruz, PhD, UC Davis, and UCLA, fellowship). He is a diplomate of clinical pharmacology, and a Fellow of the American College of Clinical Pharmacology. He is a clinical professor of ophthalmology at UC Davis, and a UC Regent Emeritus. He has authored over 300 papers and played a key role in the approval of over 50 products.

Dr Kaufman is the Ernst H. Bárány Emeritus Professor of Ocular Pharmacology and past Chair of the Department of Ophthalmology & Visual Sciences at the University of Wisconsin School of Medicine and Public Health, in Madison, Wisconsin. He is a physician-scientist, specializing in glaucoma and studying the mechanisms of aqueous humor formation and drainage, and the age-related loss of near vision. Dr Kaufman is a past President and past Executive Vice President of the Association for Research in Vision and Ophthalmology (ARVO), past President of the International Society for Eye Research (ISER), and has served on the US National Advisory Eye Council and numerous foundation and corporate scientific advisory boards. He has had continuous research funding from the US National Eye Institute for 40 years and from numerous private foundations, has authored over 375 original scientific articles and 75 book chapters, co-edited several textbooks including the most recent editions of Adler’s Physiology of the Eye, and received numerous honors and awards including the Friedenwald Award from ARVO and the Balazs Prize from ISER. He was Editor-in-Chief of Investigative Ophthalmology & Visual Science from 2008 through 2012. Dr. Kaufman also holds an honorary Doctor of Medicine degree from Uppsala University in Sweden, where he was a post-doctoral research fellow.

+ Expand all

Retinopathy Advisory Board

David S. Boyer, M.D. is a senior partner at Retina-Vitreous Associates Medical Group in Los Angeles and a Clinical Professor with the University of Southern California with an extensive research background. His professional affiliations include the Los Angeles Medical Association, Los Angeles Eye Society, American Board of Ophthalmology, Discovery Fund for Eye Research, American Academy of Ophthalmology, California Medical Association, Retina Society, Macula Society, American Medical Association and Retinitis Pigmentosa International. Dr. Boyer is a widely-published author and lecturer, and has been an advisor for several biotech and pharmaceutical companies. He is a member of the board of directors of the Research Study Club, Discovery Fund for Eye Research and has been a member of the board of directors of the American Diabetes Association Los Angeles Chapter and the Center for the Partially Sighted.

Dr. Boyer received a B.S. from the University of Illinois at Champaign, after which he completed a medical degree at the Chicago Medical School. In 1976 he finished his residency at the U.S.C. County Medical Center, and completed a retinal surgery fellowship at the Wills Eye Hospital.

Dr. Campochiaro was trained at the University of Notre Dame, Johns Hopkins School of Medicine, the University of Virginia, and Wilmer Eye Institute, joining the Wilmer Faculty in 1991. He is currently the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Institute. His major research interests are in gaining a greater understanding of the roles of peptide growth and trophic factors in the retina and retinal pigmented-epithelium with a goal of developing new treatments for proliferative retinopathies, choroidal neovascularization and retinal degenerations. Dr Campochiaro has been a scientific advisor for several biotech and pharmaceutical companies, he has more than 300 articles published in peer-reviewed medical journals.

Peter K. Kaiser, MD, is the Chaney Family Endowed Chair for Ophthalmology Research, Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine, Founder and Director of the Digital Optical Coherence Tomography Reading Center (DOCTR), and Director of the Cole Ophthalmic Imaging Center. Dr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the Vitreoretinal Department of the Cole Eye Institute at the Cleveland Clinic. Dr. Kaiser serves on numerous Scientific Advisory Boards, and on the Editorial Boards of American Journal of Ophthalmology, Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser is also editor-in-chief of Retinal Physician magazine. In addition, Dr. Kaiser is the team ophthalmologist for the Cleveland Browns (National Football League) and Cleveland Cavaliers (National Basketball Association).
Dr. Heier is the Co-President and Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston (OCB). Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He serves on the Scientific Advisory Board of several biotech and pharmaceutical companies. Dr. Heier is the lead investigator on numerous clinical trials, ranging from phase I safety and proof of concept trials to phase IV post-marketing studies Dr. Heier received his medical degree from Boston University, then did a transitional internship and ophthalmology residency at Fitzsimons Army Medical Center. Between his internship and residency, Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star. Dr. Heier then completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine.